Extracción de Reglas de Asociación en una Base de Datos Clínicos de Pacientes con Vih/Sida

En la actualidad, las personas infectadas por el VIH con acceso a tratamiento retrasan indefinidamente su entrada en la fase SIDA de la enfermedad, convirtiéndose en pacientes crónicos. Un mayor conocimiento del comportamiento del virus y de cómo afecta a las personas infectadas podría conducirnos a optimizar el tratamiento y con ello mejorar la calidad de vida de los pacientes. En este contexto aparece la minería de datos, un conjunto de metodologías que, aplicadas a grandes bases de datos, nos permiten obtener información novedosa y potencialmente útil oculta en ellas. Este trabajo de investigación realiza una primera aproximación al problema mediante la búsqueda de asociaciones en una base de datos en la que se registran las historias clínicas electrónicas de personas infectadas que son tratadas en el Hospital Clínic de Barcelona

Hospital Virtual: Sistema de información clínica y telecuidado de pacientes VIH/SIDA basado en tecnologías Web 2.0

Este artículo describe el desarrollo de un nuevo sistema de información clínica y telecuidado de pacientes VIH/SIDA que se encuentra implantado en rutina clínica dentro del Servicio de Enfermedades Infecciosas del Hospital Clínic de Barcelona. El proyecto surge ante la necesidad de unificar el sistema de información departamental del servicio y un sistema de telemedicina instalado en el hospital en 2004. Para ello se han diseñado e implementado nuevas bases de datos y dos sistemas específicos para uso de profesionales y pacientes. Además, se ha realizado una integración con el Sistema de Información del Hospital (HIS) permitiendo el acceso a todos los datos requeridos de los pacientes desde una única aplicación. Este nuevo sistema está al servicio de más de 70 profesionales sanitarios que realizan una media de 150 consultas al día disponiendo de información clínica de más de 8000 pacientes

Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naive HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012

Background: Generic drug policies are often associated with concerns about the quality and effectiveness of these products. Phase IV clinical trials may be a suitable design to assess the effectiveness and safety of generic drugs. The objective of this study was to describe the effectiveness and the safety of the generic abacavir/lamivudine and efavirenz in treatment-naïve HIV-infected patients. Methods: A monocentric, nonrandomized, open-label, phase IV study in treatment naïve HIV-infected patients 18 years or older with indication to receive abacavir/lamivudine and efavirenz were recruited from a program that provides comprehensive outpatient consultation and continuing care. The primary end-point was to achieve viral load <40 copies/mL at 12 months after baseline to assess effectiveness. Secondary end-point of the study were 1) to asses increasing in T-CD4 lymphocytes levels as accompaniment to asses effectiveness, and 2) to assess both gastrointestinal, skin, and central nervous system symptoms, and lipid profile, cardiovascular risk, renal, and hepatic function as safety profile. Data were determined at baseline, 3, 6, and 12 months. Close clinical monitoring and pharmaceutical care were used for data collection. Wilcoxon matched-pairs signed-rank test was used to compare proportions or medians. Results: Sixty patients were invited to participate in the study; 42 were enrolled and 33 completed the follow-up. Of the nine patients excluded from the study, only one was withdrawn due to adverse events. At 12 months, 31 of 42 patients (73.8 % in intention-to-treat analysis) achieved a viral load of HIV1 RNA <40 copies/mL. There was a significant increase (172 cells/mm3) in the median for CD4 T lymphocyte count. The adverse events were mild and met the safety profile for this antiretroviral regimen, mainly of central nervous system symptoms, skin rash, lipid abnormalities, and an increase of 2 % in the median of the percentage of cardiovascular risk. Conclusions: The clinical outcomes of generic version of abacavir/lamivudine and efavirenz in HIV treatment naïve patients showed the expected safety and effectiveness profile of proprietary ARV drugs. Trial registration: Registro Público Cubano de Ensayos Clínicos (RPCEC) ID: RPCEC00000202. Registered 19 November 2015.This research was made possible by contribution from the Corporación de Lucha Contra el SIDA, Cali-Colombia, and Comité para el Desarrollo de la Investigación (CODI), Universidad de Antioquia, Medellín, Colombia. In addition, Humax Pharmaceutical S.A. provided the antiretroviral drugs

Manifestaciones clínicas y métodos de diagnóstico del HIV

Las manifestaciones clínicas que presenta la persona infectada por HIV evolucionan en función del tiempo transcurrido desde el primer momento de la infección. El progresivo deterioro del sistema inmunitario, es el que marca la aparición de los diferentes grupos de manifestaciones clínicas. Un nuevo grupo se ha incorporado a los ya existentes, se trata de los efectos secundarios derivados de los tratamientos antirretrovirales

Escola catalana

Resumen de los autores en catalánEl CEIP Eladi Homs de Valls (Alt Camp) abrió sus puertas como CERE en integración educativa el curso 85-86, con el objetivo de dar respuesta a los alumnos con necesidades educativas especiales de la comarca en un entorno educativo normalizado dentro del sistema educativo ordinario. El artículo amplia el tema.CataluñaES

Tuberculosis in European HIV patients: Efficacy of three vs four drugs

0info:eu-repo/semantics/nonPublishe

Tuberculosis in European HIV patients: Efficacy of three vs four drugs

info:eu-repo/semantics/nonPublishe

Changes in Cognitive Function over 96 Weeks after Initiating Darunavir/Ritonavir with Either Raltegravir or Tenofovir-Emtricitabine: NEAT 001 / ANRS 143 Randomised Controlled Study

For the NEAT 001/ANRS 143 Study Groupinfo:eu-repo/semantics/nonPublishe

Random period arc-induced long-period fiber gratings

Background: Twice-daily raltegravir with once-daily tenofovir-emtricitabine is an effective initial antiretroviral regimen for patients with HIV-1. On the basis of pharmacokinetic data suggesting efficacy of once-daily raltegravir and because adherence is often improved with once-daily dosing, we aimed to compare these dosing schedules. Methods: In our international, double-blind, randomised, phase 3 non-inferiority study, we enrolled antiretroviral-naive patients with HIV RNA loads of more than 5000 copies per mL and no baseline resistance to tenofovir or emtricitabine at 83 centres worldwide. We randomly allocated patients (1:1) by use of a computer-generated sequence to receive raltegravir once daily (two 400 mg tablets taken together every 24 h), or twice daily (one 400 mg tablet every 12 h), both in combination with once-daily co-formulated tenofovir 300 mg plus emtricitabine 150 mg. The primary outcome was virological response at 48 weeks (viral RNA loads <50 copies per mL) in patients who received at least one dose of study drug, counting non-completers as failure. We assessed non-inferiority in terms of the proportion of patients in both treatment groups who achieved the primary outcome, with a non-inferiority margin of -10%. This study is registered with ClinicalTrials.gov, number NCT00745823. Findings: From Oct 15, 2008, to Nov 2, 2009, we randomly allocated 775 patients, of whom 382 (99%) of 386 patients in the once-daily group and 388 (99%) of 389 in the twice-daily group received at least one dose of study drug. At baseline, 304 (39%) of 770 treated patients had viral loads of more than 100 000 copies per mL and 188 (24%) had CD4 cell counts of fewer than 200 cells per ?L. 318 (83%) of 382 patients in the once-daily group had virological response compared with 343 (89%) of 386 in the twice-daily group (difference -5 7%, 95% CI -10 7 to -0 83; p=0 044). Serious adverse events were reported in 26 (7%) of 382 once-daily recipients and 40 (10%) of 388 twice-daily recipients, and adverse events leading to discontinuation occurred in four (1%) patients in each group. Interpretation: Despite high response rates with both regimens, once-daily raltegravir cannot be recommended in place of twice-daily dosing. Funding: Merck. " 2011 Elsevier Ltd.",,,,,,"10.1016/S1473-3099(11)70196-7",,,"http://hdl.handle.net/20.500.12104/44049","http://www.scopus.com/inward/record.url?eid=2-s2.0-81855166275&partnerID=40&md5=6f046390ce51f7b7d60e001a291cdbd0",,,,,,"12",,"The Lancet Infectious Diseases",,"90